Hepatorenal Syndrome

Flint A. Clinical report on hydro-peritoneum: based on analysis of forty-six cases. Am J Med Sci 1863; 45: 306-39.

Gines A, Escorsell A, Gines P, Salo J, Jimenez W, Inglada L, et al. Incidence, predictive factors and prognosis of the hepatorenal syndrome in cirrhosis with ascites. Gastroenterology 1993; 105: 229-36.

Arroyo V, Gines P, Gerbes AL, Dudley FJ, Bentilini P, Laffi G, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. Hepatology 1996; 23: 164-73.

Martin PY, Gins P, Schrier RW. Nitric oxide as a mediator of hemodynamic abnormalities and sodium and water retention in cirrhosis. N Engl J Med 1998; 339: 533–41.

Gins P, Arroyo V. Hepatorenal syndrome. J Am Soc Nephrol 1999; 10: 1833-9.

Epstein M. Hepatorenal syndrome: emerging perspectives of pathophysiology and therapy. J Am Soc Nephrol 1994; 4: 1735–53.

Blendis L, Wong F. The natural history and management of hepatorenal disorders: from pre-ascites to hepatorenal syndrome. Clin Med 2003; 3: 154-9.

Lieberman FL. Functional renal failure in cirrhosis. Gastroenterology 1970; 58: 108-10.

Koyama S, Kanai K, Aibiki M, Fujita T. Reflex increase in renal nerve activity during acutely altered portal venous pressure. J Auton Nerv Syst 1988; 23: 55-62.

Schrier RW, Arroyo V, Bernadi M, Epstein M, Henriksen JH, Rodes J. Peripheral arterial vasodilatation hypothesis: A proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 1988; 8: 1151-7.

Vallance P, Moncada S. Hyperdynamic circulation in cirrhosis: A role for nitric oxide? Lancet 1991; 337:776-8.

Guarner C, Soriano G, Tomas A, Bulbena O, Novella MT, Balanzo J, et al. Increased serum nitrite and nitrate levels in patients with cirrhosis: Relationship to endotoxaemia. Hepatology 1993; 18: 1139-41.

Guevara M, Gins P, Jimenez W, Sort P, Fernแndez-Esparrach G, Escorsell A, et al. Increased adrenomedullin levels in cirrhosis: Relationship with hemodynamic abnormalities and vasoconstrictor systems. Gastroenterology 1998; 114: 336-43.

Epstein M, Berck DP, Hollenberg NK, Adams DF, Chalmess TG, Abrams HL. Renal failure in patient with cirrhosis. The role of active vasoconstriction. Am J Med 1970; 49: 175-85.

Schroeder ET, Eich RH, Smulyan H, Gould AB, Gabuzda GJ. Plasma rennin level in hepatic cirrhosis. Am J Med 1970; 49: 186-91.

Klahr S. Role of arachidonic acid metabolites in acute renal failure and sepsis. Nephrol Dial Transplant 1994; 9: 52-6.

Keshavazian A, Holmes EW, Patel M, Iber F, Fields JZ, Pethkar S. Leaky gut in alcoholic cirrhosis: A possible mechanism for alcohol-induced liver damage. Am J Gastroenterol 1999; 94: 200-7.

Bellomo R, Chapman M, Finfer S, et al. Low-dose dopamine in patients with early renal dysfunction: A placebocontrolled randomized trail. Lancet 2000; 356: 2139-43.

Bennett WM, Keeffe E, Melnyk C, Mahler D, R๖sch J, Porter GA. Response to dopamine hydrochloride in the hepatorenal syndrome. Arch Intern Med 1975; 135: 964-7.

Wilson JR. Dopamine in the hepatorenal syndrome. JAMA 1977; 238: 2719-20.

Holt S, Goodier D, Marley R, Patch D, Burroughs A, Fernando B, et al. Improvement in renal function in hepatorenal syndrome with N-acetylcysteine. Lancet 1999; 353: 294-5.

Conesa EL, Valero F, Nadal JC, Fenoy FJ, Lopez B, Arregui B, et al. N-acetyl-L-cysteine improves renal medullary hypoperfusion in acute renal failure. Am J Physiol Regul Integr Comp Physiol 2001; 281: R730-7.

Guevara M, Gins P, Fernandez-Esparrach G, Sort P, Salmeron JM, Jimenez W, et al. Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion. Hepatology 1998; 27: 35–41.

Ortega R, Gins P, Uriz J, Cแrdenas A, Calahorra B, De Las Heras D, et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 2002; 36: 941–8.

Gins P, Cแrdenas A, Arroyo V, Rodes J. Management of cirrhosis and ascites. N Engl J Med 2004; 350: 1646–54.

Gulberg V, Bilzer M, Gerbes AL. Long-term therapy and retreatment of hepatorenal syndrome type I with ornipressin and dopamine. Hepatology 1999; 30: 202-4.

Lenz K, H๖rtnagl H, Druml W, Reither H, Schmid R, Schneeweiss B, et al. Ornipressin in the treatment of function renal failure in decompensated liver cirrhosis. Gastroenterology 1991; 101: 1060-7.

Hadengue A, Gadano A, Moreau R, Giostra E, Durand F, Valla D, et al. Beneficial effects of the 2-day administration of terlipressin in patients with cirrhosis and hepatorenal syndrome. J Hepatol 1998; 29: 565-70.

Uriz J, Gins P, Cardenas A, Sort P, Jimenez W, Salmer๓n JM, et al. Terlipressin plus albumin infusion: An effective and safe therapy of hepatorenal syndrome. J Hepatol 2000; 33: 43-8.

Mulkay JP, Louis H, Donckier V. Long-term terlipressin administration improves renal function failure in cirrhotic patients with type I hepatorenal syndrome: A pilot study. Acta Gastroenterol Belg 2001; 64: 15-9.

Ng CK, Chan MH, Tai MH, Lam CW. Hepatorenal syndrome. Clin Biochem Rev 2007; 28: 11-7.

Tandon P, Bain VG, Tsuyuki RT, Klarenbach S. Systematic review: renal and other clinically relevant outcomes in hepatorenal syndrome trials. Aliment Pharmacol Ther 2007. 25: 1017-28.

Colle I, Moreau R, Pessione F, Rassiat E, Heller J, Chagneau C, et al. Relationship between haemodynamic alterations and the development of ascites or refractory ascites in patients with cirrhosis. Eur J Gastroenterol Hepatol 2001; 13: 251-6.

Rosch J, Keller FS. Transjugular intrahepatic portosystemic shunt: Present status, comparison with endoscopic therapy and shunt surgery, and future prospective. World J Surg 2001; 25: 337-45.

Rossle M, Haag K, Ochs A, Sellinger M, Noldge G, Perarnau JM,et al. The transjugular intrahepatic portosystemic stent-shunt procedure for variceal bleeding. N Engl J Med 1994; 330: 165-71.

Mitzner SR, Stange J, Klammt S, Risler T, Erley CM, Bader BD, et al. Improvement of hepatorenal syndrome with extracorporeal albumin dialysis MARS: results of a prospective, randomized, controlled clinical trial. Liver Transpl 2000; 6: 277-86.

Xu X, Ling Q, Zhang M, Gao F, He Z, You J, et al. Outcome of patients with hepatorenal syndrome type 1 after liver transplantation: Hangzhou experience. Transplantation 2009; 87: 1514-9.

Arroyo V, Guevara M, Gins P. Hepatorenal syndrome in cirrhosis: pathogenesis and treatment. Gastroenterology 2002; 122: 1658-76.

Mukherjee S. Hepatorenal syndrome. Available from http:www.emedicine.com. Retrieved on 2009-08-02.

Velamati PG, Herlong HF. Treatment of refractory ascites. Curr Treat Options Gastroenterol 2006; 9: 530–7.

Ascites In: Sherlock S, James D, eds. Sherlock’s Diseases of the Liver and Biliary system. 11th ed. Philadelphia: Blackwell, 2002. p.140-6.